TY - JOUR
T1 - Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients
AU - Lorenzo, Giuseppe Di
AU - Cartenì, Giacomo
AU - Autorino, Riccardo
AU - Gonnella, Antonio
AU - Perdonà, Sisto
AU - Ferro, Matteo
AU - Longo, Nicola
AU - Rescigno, Pasquale
AU - Doria, Francesca
AU - Faiella, Adriana
AU - Altieri, Vincenzo
AU - Palmieri, Giovannelia
AU - Imbimbo, Ciro
AU - Mirone, Vincenzo
AU - De Placido, Sabino
PY - 2009/4
Y1 - 2009/4
N2 - The objective of this study was to evaluate the use of paclitaxel in patients with advanced squamous cell penile cancer previously treated with neoadjuvant cisplatin-based chemotherapy. This was a single-arm, phase II, multicenter study. Patients were treated with 175mg/m2 paclitaxel at a 3-week interval, until disease progression or irreversible toxicity. The primary end point was the objective response rate. Secondary end points were safety, progression-free survival, and overall survival. Twelve patients were enrolled. Partial responses were observed in 25% (3 of 12) of patients (95% confidence interval: 12-40%). Grade 3 neutropenia and oral mucositis were the most common side effects, each noted in three patients. Median progression-free survival was 4 months (range 2-6 months) and median overall survival was 6 months (range 3-10 months). Paclitaxel is well tolerated and associated with promising efficacy. Further trials, also in a neoadjuvant setting, are needed to corroborate our preliminary findings.
AB - The objective of this study was to evaluate the use of paclitaxel in patients with advanced squamous cell penile cancer previously treated with neoadjuvant cisplatin-based chemotherapy. This was a single-arm, phase II, multicenter study. Patients were treated with 175mg/m2 paclitaxel at a 3-week interval, until disease progression or irreversible toxicity. The primary end point was the objective response rate. Secondary end points were safety, progression-free survival, and overall survival. Twelve patients were enrolled. Partial responses were observed in 25% (3 of 12) of patients (95% confidence interval: 12-40%). Grade 3 neutropenia and oral mucositis were the most common side effects, each noted in three patients. Median progression-free survival was 4 months (range 2-6 months) and median overall survival was 6 months (range 3-10 months). Paclitaxel is well tolerated and associated with promising efficacy. Further trials, also in a neoadjuvant setting, are needed to corroborate our preliminary findings.
KW - Activity and toxicity
KW - Metastatic penile cancer
KW - Paclrtaxel
UR - http://www.scopus.com/inward/record.url?scp=63449096646&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=63449096646&partnerID=8YFLogxK
U2 - 10.1097/CAD.0b013e328329a293
DO - 10.1097/CAD.0b013e328329a293
M3 - Article
C2 - 19262371
AN - SCOPUS:63449096646
SN - 0959-4973
VL - 20
SP - 277
EP - 280
JO - Anti-Cancer Drugs
JF - Anti-Cancer Drugs
IS - 4
ER -